摩根士丹利将 Zentalis Pharmaceuticals (ZNTL) 的评级定为“同等权重”，并将其目标价从 38 美元下调至 8 美元。 Zentalis Pharmaceuticals (ZNTL) received an Equal Weight rating from Morgan Stanley, reducing their target price from $38 to $8.

摩根士丹利将 Zentalis Pharmaceuticals (ZNTL) 的评级定为“同等权重”，并将其之前的目标价从 38 美元下调至 8 美元。 Zentalis Pharmaceuticals (ZNTL) received an Equal Weight rating from Morgan Stanley, downgrading their previous target price from $38 to $8. 包括富国银行、Stifel Nicolaus 和 Wedbush 在内的几家研究公司都下调了 ZNTL 的目标价，平均评级仍为持有，为 11.33 美元。 Several research firms, including Wells Fargo, Stifel Nicolaus, and Wedbush, reduced their price objectives for ZNTL, with average ratings remaining a Hold at $11.33. 尽管被下调预期，但第一季度每股收益 0.14 美元仍比普遍预期的 0.77 美元高出 0.91 美元，营收 4056 万美元也高于预期的 3500 万美元。 Despite the downgrades, Q1 earnings of $0.14 per share surpassed the consensus estimate of ($0.77) by $0.91, and revenue of $40.56M exceeded the expected $35M.